Perricone v. Medicis Pharmaceutical Corp.
Decision Date | 20 December 2005 |
Docket Number | No. 05-1023.,No. 05-1022.,05-1022.,05-1023. |
Citation | 432 F.3d 1368 |
Parties | Nicholas V. PERRICONE, M.D., Plaintiff-Appellant, v. MEDICIS PHARMACEUTICAL CORPORATION, Defendant-Cross Appellant. |
Court | U.S. Court of Appeals — Federal Circuit |
Raphael V. Lupo, McDermott Will & Emery, of Washington, DC, argued for plaintiff-appellant. With him on the brief were Charles R. Work, Mark G. Davis and David A. Spenard. Of counsel were Mary C. Chapin and Evan Parke.
William J. McNichol, Jr., Reed Smith LLP, of Philadelphia, Pennsylvania, argued for defendant-cross appellant. With him on the brief were Tracy Zurzolo Frisch, Maryellen Feehery and Heather A. Ritch. Of counsel was Charles L. Becker.
Before RADER, BRYSON, and LINN, Circuit Judges.
Opinion for the court filed by Circuit Judge RADER.
On summary judgment, the United States District Court for the District of Connecticut, No. 3:99-CV-01820, determined that all of the asserted claims of Dr. Nicholas V. Perricone's U.S. Patent Nos. 5,409,693 (the '693 patent) and 5,574,063 (the '063 patent) are invalid and, as to the '693 patent, not infringed. Perricone v. Medicis Pharm. Corp., 267 F.Supp.2d 229 (D.Conn.2003). Dr. Perricone seeks reversal of those judgments while Medicis Pharmaceutical Corporation cross-appeals the district court's refusal to declare the case exceptional under 35 U.S.C. § 285 and to award Medicis its attorney fees. Because the district court erred in its anticipation analysis with respect to claims 1-4 and 7 of the motion under § 285.
Dr. Perricone's patents claim methods of treating or preventing sunburns (the '693 patent) and methods of treating skin damage or disorders (the '063 patent). The 693 patent, col. 4, ll. 4-6; '063 patent, col. 4, ll. 10-12. Upon reaching the lipid-rich layers of skin, the ascorbyl fatty acid ester produces a number of beneficial effects ranging from the acceleration of collagen synthesis to the scavenging of oxygen-containing radicals caused by exposure to damaging ultraviolet radiation. See '693 patent, col. 5, ll. 30-35, col. 6, ll. 35-50; '063 patent, col. 6, ll. 3-15, col. 7, ll. 30-45.
In 1999, Dr. Perricone sued Medicis, alleging that Medicis infringed both the motions and denied Dr. Perricone's. Id. at 249.
The district court's opinion and the parties' briefs before this court do not disclose the disposition of each claim of the '693 and '063 patents. The district court's opinion appears to invalidate all of the asserted claims of both patents, yet grants summary judgment of non-infringement only for the '693 patent. See id. Dr. Perricone's opening brief suggests that the district court's non-infringement ruling applies to the asserted claims of both patents. Dr. Perricone's opening brief at 1. Nevertheless, this court need not determine the correct status of each claim. Rather, this court confines its rulings to reversal of a clearly identifiable subset of the '693 claims and trusts the parties to resolve any uncertainty on remand.
This court reviews a district court's grant of summary judgment without deference and a denial of summary judgment for an abuse of discretion, Electromotive Div. of Gen. Motors Corp. v. Transp. Sys. Div. of Gen. Elec. Co., 417 F.3d 1203, 1209 (Fed.Cir.2005), drawing all reasonable inferences in favor of the nonmovant. This court gives due weight to a patent's presumed validity under 35 U.S.C. § 282 (2000), requiring an accused infringer to prove invalidity by clear and convincing evidence. Geneva Pharm., Inc. v. Glaxosmithkline PLC, 349 F.3d 1373, 1377 (Fed.Cir.2003). This court reviews double patenting without deference. Georgia-Pacific Corp. v. U.S. Gypsum Co., 195 F.3d 1322, 1326 (Fed.Cir.1999).
The double patenting doctrine generally prevents a patentee from receiving two patents for the same invention. Thus, this doctrine polices the proper application of the patent term for each invention. The proscription against double patenting takes two forms: statutory and non-statutory. Statutory, or "same invention," double patenting is based on the language in § 101 of the Patent Act mandating "a patent" for any new and useful invention. 35 U.S.C. § 101 (2000); In re Goodman, 11 F.3d 1046, 1052 (Fed.Cir.1993) () (citations omitted). Non-statutory, or "obviousness-type," double patenting is a judicially created doctrine adopted to prevent claims in separate applications or patents that do not recite the "same" invention, but nonetheless claim inventions so alike that granting both exclusive rights would effectively extend the life of patent protection. Gerber Garment Tech., Inc. v. Lectra Sys., Inc., 916 F.2d 683, 686 (Fed.Cir.1990) (citing In re Thorington, 57 C.C.P.A. 759, 418 F.2d 528, 534 (1969)). This case involves double patenting in this latter category.
Claim 1 of the '693 patent recites:
1. A method for treating skin sunburn comprising topically applying to the skin sunburn a fatty acid ester of ascorbic acid effective to solubilize in the lipid-rich layers of the skin an amount effective to scavenge therefrom free radicals present as a result of transfer of energy to the skin from the ultraviolet radiation which produced said sunburn.
'693 patent, col. 7. Meanwhile, claim 9 of the '063 patent recites:
9. A method for the treatment of skin damaged or aged by oxygen-containing free radicals or oxidative generation of biologically active metabolites which comprises topically applying to affected skin areas a composition containing an effective amount of an ascorbyl fatty acid ester in a dermatologically acceptable, fat-penetrating carrier such that the ester is percutaneously delivered to lipid-rich layers of the skin.
'063 patent, cols. 8-9. The district court found claim 9 of the '063 patent invalid under the non-statutory double patenting doctrine in view of claim 1 of the '693 patent. In reaching that conclusion, the district court first identified differences between the two claims:
(1) claim 9 of the '063 patent teaches a method for treatment of certain skin disorders, while claim 1 of the '693 patent teaches a method for treatment of sunburn; (2) claim 9 of the '063 patent recites the use of "an effective amount of an ascorbyl fatty acid ester . . .," while claim 1 of the '693 patent teaches applying an ascorbyl fatty acid ester "effective to solubilize in the lipid-rich layers of the skin an amount effective to scavenge free radicals present as a result of the transfer of energy to the skin from the ultraviolet radiation which produced [the] sunburn"; and (3) claim 9 of the '063 patent recites the use of "a dermatologically acceptable, fat-penetrating carrier such that the ester is percutaneously delivered to lipid-rich layers of the skin," while the '693 patent does not explicitly recite the use of a carrier.
Perricone, 267 F.Supp.2d at 240. The district court analyzed those distinctions. In the first place, the district court noted that "sunburn is a species of the genus of skin disorders" covered by the '063 patent. Id. Next, consulting the specifications of both patents, the district court concluded that the claimed effective amount in the '063 patent falls within the ranges of effective amounts in the '693 patent. Finally, the district court construed the ...
To continue reading
Request your trial-
Zimmer Surgical, Inc. v. Stryker Corp., Civil Action No. 16-679-RGA
...even after a finding that the challenged patent is invalid for obviousness-type double patenting."); Perricone v. Medicis Pharm. Corp. , 432 F.3d 1368, 1375 (Fed. Cir. 2005) ("[a] terminal disclaimer can indeed supplant a finding of invalidity for double patenting"). Boehringer suggests tha......
-
Pfizer Inc. v. Teva Pharmaceuticals Usa, Inc.
...916 F.2d 683, 686 (Fed.Cir.1990) (citing In re Thorington, 57 C.C.P.A. 759, 418 F.2d 528, 534 (1969)). Perricone v. Medicis Pharm. Corp., 432 F.3d 1368, 1372-1373 (Fed.Cir.2005). This case involves double patenting in this latter category. Specifically, Teva alleges that the '068 Patent (co......
-
Kilopass Tech., Inc. v. Sidense Corp.
...significant flexibility that critics of our § 285 jurisprudence often overlook. Our decision in Perricone v. Medicis Pharmaceutical Corp., 432 F.3d 1368 (Fed.Cir.2005), reinforces the fact that attorneys' fee determinations retain a great deal of flexibility, even after Brooks Furniture. In......
-
Applications v. Brookwood Companies Inc
...Patenting Under 35 U.S.C. § 101, an inventor may not obtain more than one patent for the “same invention.” Perricone v. Medicis Pharm. Corp., 432 F.3d 1368, 1372-73 (Fed.Cir.2005). Double-patenting is a basis for a finding of patent invalidity, and like other invalidity claims, the party as......
-
Federal Circuit Finds Obviousness-Type Double Patenting Without Common Ownership
...so alike that granting both exclusive rights would effectively extend the life of patent protection." Perricone v. Medicis Pharm. Corp., 432 F.3d 1368, 1373 (Fed. Cir. 2005) (citation omitted). It prohibits the issuance of claims in a second patent that are "not patentably distinct from the......
-
In Re Hubbell Puts Inventors At A Disadvantage
...so alike that granting both exclusive rights would effectively extend the life of patent protection." Perricone v. Medicis Pharm. Corp., 432 F.3d 1368, 1373 (Fed. Cir. 2005). It prohibits the issuance of claims in a second patent that are "not patentably distinct from the claims of the firs......
-
Will SawStop "Nick" OTDP?
...so alike that granting both exclusive rights would effectively extend the life of patent protection." Perricone v. Medicis Pharm. Corp., 432 F.3d 1368, 1373 (Fed. Cir. 2005). To obtain claims in a subsequent patent application shared by common owners, the application must recite claims that......
-
Justices Could Prompt A Seismic Shift In Double Patenting
...is under 35 U.S.C. ' 101 because an inventor is entitled to a single patent for an invention."). 14. Perricone v. Medicis Pharm. Corp. , 432 F.3d 1368, 1373 (Fed. Cir. 15. 319 F.2d 225, 231 n.4 (CCPA 1963). 16. Procter & Gamble Co. v. Teva Pharm. USA, Inc. , 566 F.3d 989, 999 (Fed. Cir. 200......
-
Copying copyright's willful infringement standard: a comparison of enhanced damages in patent law and copyright law.
...punitive purpose of enhanced damages for willful infringement), cert. denied, 128 S. Ct. 1445 (2008); Perricone v. Medicis Pharm. Corp., 432 F.3d 1368, 1380-81 (Fed. Cir. 2005) (recognizing punitive purpose of attorney fee award); Beckman Instr., Inc. v. LKB Produkter AB, 892 F.2d 1547, 155......